Know Cancer

or
forgot password

Study of Topoisomerase Inhibition in the Treatment of Acute Leukemia


Phase 2
18 Years
60 Years
Not Enrolling
Both
Leukemia, Non-Hodgkin's Lymphoma

Thank you

Trial Information

Study of Topoisomerase Inhibition in the Treatment of Acute Leukemia

Inclusion Criteria


- Patients in the following disease categories will be considered eligible for this
study: *Any acute leukemia beyond an initial attempt to induce a remission or after
relapse, *Chronic Myelogenous Leukemia in Blast Phase, *Refractory Multiple Myeloma,
*Refractory non-Hodgkin's and Hodgkin's Lymphoma

- Patients must be more than 14 days beyond prior myelotoxic chemotherapy.

- Several other eligibility criteria apply.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Authority:

United States: Federal Government

Study ID:

CADE-RCD1

NCT ID:

NCT00100477

Start Date:

December 1998

Completion Date:

Related Keywords:

  • Leukemia
  • Non-Hodgkin's Lymphoma
  • Leukemia
  • Lymphoma
  • Lymphoma, Non-Hodgkin

Name

Location

Malcolm Randall VA Medical CenterGainesville, Florida  32608